Genetic Testing

We know from twin and familial studies that keratoconus has a genetic component. First-degree relatives of people with keratoconus have a 15- to 67-fold greater risk for keratoconus than the general population.

A comprehensive approach to screening for breast cancer and working with patients to reduce their lifestyle risks can save more lives, Lisa Larkin, MD, FACP, NCMP, IF, said during the NAMS Annual Meeting.

Even among insured patients, germline BRCA testing is underutilized in women with newly diagnosed ovarian cancer, according to a study presented at the virtual ASCO Annual Meeting.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the DESTINY-Lung01 study presented at ESMO 2021.

Among people who ordered a genetic test for dyslipidemia, younger people were more likely to have a positive result than older people, according to a presentation at the National Lipid Association Scientific Sessions.

Genetic testing can be useful for some patients with dyslipidemia, but many factors must be considered when selecting a test, according to a National Lipid Association scientific statement.

The prevalence of clinical genetic testing is rising; therefore, the American Heart Association has issued guidance on the use, ethics and timing of pediatric genetic testing for heritable CVDs.

Precision medicine via genetic testing and family history can reduce uncertainty in diabetes diagnoses and allow more targeted therapy, improving patient-centered outcomes, such as mental health and quality of life, according to a speaker.

Sharing results of genetic tests for cardiomyopathy with adolescents does not appear to negatively impact family functioning scores, researchers reported.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the clinical implications of the BEAT-AML trial and genetic testing in AML.